What Invictus Therapeutics does

Invictus Therapeutics is a privately held, clinical-stage pharmaceutical company incorporated in 2025 and headquartered in Warwick, Rhode Island. It is developing a portfolio of next-generation insulin analogs and complementary miniaturized insulin pump technology, originating from more than ten years of research conducted in the laboratory of founder Michel Weiss, MD, PhD, MBA. The company's stated purpose is to address unmet needs of insulin-dependent diabetic patients by transitioning these laboratory-stage assets into clinical development.

The company's core asset is a lead insulin analog designed for use in insulin pumps and automated insulin delivery (AID) systems. Disclosed technical characteristics include best-in-class pharmacokinetics, a stable monomeric formulation at up to 10x standard insulin concentration, and stability at room temperature (30°C/86°F) for at least one year. Additional pipeline assets include additional ultra-stable insulin formulations and miniaturized pump technology, positioning the company toward a drug-device combination play rather than a single-asset insulin analog.

Commercially, Invictus is pre-revenue. Its business model is pharmaceutical development: in January 2026 it received a milestone-based Industry Discovery and Development Partnership award from Breakthrough T1D (formerly JDRF) and initiated a first-in-human Phase 1 clinical trial of the lead insulin analog, conducted by Profil, a German metabolic clinical research organization. Future commercialization, per the company's own communications, is planned through pharmaceutical distribution partnerships and healthcare provider networks rather than proprietary sales channels. Pricing is undisclosed, no customers are named, and there is no current product on the market.

Name

Invictus Therapeutics

Legal name

Invictus Therapeutics, LLC

Website

https://invictustx.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

Invictus Therapeutics is a clinical-stage pharmaceutical company developing next-generation ultra-rapid, high-concentration, room-temperature-stable insulin analogs and miniaturized pump technology for insulin-dependent diabetic patients, particularly insulin pump and automated insulin delivery users.

Ownership category

akta.pro rank

Product category

Insulin Therapeutics / Diabetes Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF)

akta.pro secondary industry

Insulin Pumps & Patch Pumps (HLAHAIAG)

Keywords

• Insulin analog development
• Automated insulin delivery
• Diabetes therapeutics
• Insulin pump therapy
• Clinical stage biopharmaceutical

Headquarters

HQ city

West Warwick

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Once approved, the company plans to commercialize its insulin analog portfolio through pharmaceutical product sales, likely through partnerships with established pharmaceutical distributors and healthcare providers in the diabetes care market.

Go-to-market motion1 record

Marketing channels2 records

Core offering

Invictus Therapeutics develops next-generation insulin analogs engineered for automated insulin delivery and closed-loop insulin pump systems. The lead candidate features ultra-rapid pharmacokinetics, a stable monomeric formulation up to 10x standard insulin concentration, and room-temperature stability (30°C/86°F) for at least one year, and is currently advancing through a Phase 1 first-in-human clinical trial conducted at Profil in Germany. The pipeline also includes additional ultra-stable insulin formulations and a complementary miniaturized pump technology asset.

Product overview

Invictus Therapeutics is developing a portfolio of next-generation insulin analogs and pump technologies originating from research conducted by Michel Weiss, MD, PhD, MBA. The core product is a lead insulin candidate featuring ultra-rapid action, high concentration, and room-temperature stability for automated insulin delivery systems. Additional assets include ultra-stable insulin formulations and miniaturized pump technology. The products are designed to address unmet needs in the insulin pump market, particularly for patients requiring improved pharmacokinetics and stability profiles.

Differentiator

Problem solved

Functional benefit

Products and services

• Lead Candidate Insulin Analog A novel insulin analog designed for insulin pump users featuring best-in-class pharmacokinetics, a stable monomeric formulation up to 10x standard insulin concentration, and stability at room temperature (30°C/86°F) for at least one year. It is engineered as an ultra-rapid, concentrated, stable insulin for next-generation automated insulin delivery systems and closed-loop pump systems, targeting insulin-dependent diabetic patients, particularly those using insulin pumps.
• Ultra-Stable Insulins Additional ultra-stable insulin formulations in the development pipeline designed to improve outcomes for insulin-dependent diabetic patients. These are pipeline assets extending Invictus' insulin platform beyond the lead candidate to broaden coverage of the insulin-dependent patient population.
• Miniaturized Pump Technology Miniaturized insulin pump technology designed to work with next-generation insulin analogs, aimed at improving therapy for the growing number of insulin-dependent diabetics worldwide. It complements the company's insulin analog portfolio by addressing device-side miniaturization alongside pharmacokinetic and stability improvements.

Quantifiable outcome

• Stable monomeric formulation up to 10x standard insulin
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• ProfilcoreStrategic or Co-development Partner · 12 January 2026Profil, a leading clinical research organization specializing in metabolic and diabetes studies based in Germany, is conducting the Phase 1 clinical trial for Invictus Therapeutics' next-generation insulin analog.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Bigfoot Biomedical: Bigfoot is an emerging AID-focused company building smart insulin delivery systems. Comparable as a smaller player pursuing the same integrated drug-device vision that Invictus's bundled insulin-plus-pump portfolio implies.
• Zealand Pharma: Zealand Pharma has historically partnered with Sanofi on insulin programs and develops peptide therapeutics including diabetes-relevant assets. Comparable as a peptide/drug developer with insulin-adjacent programs and a similar partnering-oriented commercial model.

Broad incumbents

• Sanofi: Sanofi markets rapid-acting insulin Apidra and has historically been a significant player in the insulin market. Comparable as a broad incumbent whose pipeline and pricing decisions influence the competitive landscape for any new insulin analog.
• Medtronic Diabetes: Medtronic's diabetes division offers the MiniMed insulin pump and AID systems. Comparable as a large incumbent pump/AID player whose closed-loop algorithms depend on rapid-acting insulins like the one Invictus is developing.
• Tandem Diabetes Care: Tandem develops the t:slim X2 insulin pump with Control-IQ AID technology. Comparable as a leading AID pump manufacturer and a potential commercial partner or competitor for an AID-optimized insulin analog.
• Eli Lilly: Manufacturer of Humalog and Lyumjev (ultra-rapid lispro), and a leading developer of insulin formulations and AID ecosystem products. Comparable as a major incumbent that defines the bar Invictus's lead analog must exceed in PK performance.
• Novo Nordisk: Global leader in insulin and diabetes care with rapid-acting analogs such as Fiasp and NovoRapid, plus an active pipeline in glucose-responsive and AID-friendly insulins. Comparable as the dominant incumbent whose next-generation rapid analogs Invictus must differentiate against.
• Insulet Corporation: Insulet manufactures the Omnipod tubeless insulin pump, a leading AID platform. Comparable as a pump-side incumbent whose insulin-formulation requirements shape the opportunity space Invictus's AID-optimized analog targets.

Direct peers

• MannKind Corporation: MannKind develops and commercializes Afrezza, an ultra-rapid-acting inhaled insulin. Comparable because both companies are focused on next-generation, faster-onset insulin formulations designed to improve post-meal glucose control and to fit novel delivery platforms.
• Adocia: Adocia is a clinical-stage biotech developing ultra-rapid and prandial insulin formulations (e.g., BioChaperone lispro) for pumps and AID systems. Directly comparable to Invictus as a competitor in the niche of AID-optimized insulin analog development.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/wix
• Facebookfacebook.com/wix
• Instagraminstagram.com/wix
• TikToktiktok.com/@wix

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Invictus Therapeutics